GlassScriptPhysician profile
Katrina Herman Akin
NPI 1336674068
$12,639.24
in general payments reported to CMS, 2019-2025
51 companies · $3,198 in 2025
The $3,198 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $751 · 2022: $2,440 · 2023: $2,811 · 2024: $3,440 · 2025: $3,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,306 · Education: $142.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,305.89 |
| Education | $141.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,875.97 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Ucb, INC. | $855.29 | 2021-2025 | Briviact, Rystiggo, Nayzilam |
| Mdd US Operations, LLC | $700.92 | 2022-2025 | Gocovri, Gocovri |
| Argenx US, INC. | $698.09 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Livanova USA, INC. | $615.01 | 2022-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Pfizer INC. | $479.09 | 2023-2025 | |
| Sk Life Science, INC. | $439.20 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $427.08 | 2021-2025 | Austedo Xr, Austedo, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $417.43 | 2024-2025 | |
| Acadia Pharmaceuticals INC | $401.09 | 2022-2025 | Nuplazid, Daybue |
| Genzyme Corporation | $400.10 | 2021-2024 | |
| Lilly USA, LLC | $376.17 | 2021-2025 | Amyvid, Emgality, Kisunla |
| Eisai INC. | $329.61 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $326.79 | 2022-2024 | Ingrezza, Ongentys |
| Otsuka America Pharmaceutical, INC. | $324.71 | 2023-2025 | Rexulti |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katrina Akin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.